Literature DB >> 26357854

The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer.

Yoon Yang Jung1, Yu Kyung Lee1, Ja Seung Koo1.   

Abstract

INTRODUCTION: Beclin 1 plays a crucial role in autophagy via the Beclin 1 interactome, and is involved in various biological processes such as protein sorting, chemokinesis, and cell death. Via these biologic functions, Beclin 1 contributes to both tumor suppression and tumor progression. AREAS COVERED: Beclin 1 plays a key biologic function on cell homeostasis and affects tumorigenesis. In this review, detailing up-to-date knowledge on the tumorigenic role of Beclin 1, its implication in breast cancer, and its utility as a breast cancer-specific drug target is discussed. EXPERT OPINION: Because Beclin 1 is expressed in breast cancer cells, Beclin 1 could be a unique, effective drug target for the prevention and treatment of breast cancer. However, the expression of Beclin 1 varies according to cancer molecular subtypes, and Beclin 1 is involved in both breast cancer suppression and tumor progression; therefore, the decision of using a Beclin 1 inducer or inhibitor should be made based on breast cancer stage and subtype.

Entities:  

Keywords:  Beclin 1; autophagy; breast cancer; targeted drug therapy

Mesh:

Substances:

Year:  2015        PMID: 26357854     DOI: 10.1517/14728222.2016.1085971

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  8 in total

1.  Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.

Authors:  Ludovica Taglieri; Francesca De Iuliis; Anna Giuffrida; Sabrina Giantulli; Ida Silvestri; Susanna Scarpa
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

2.  Allyl Isothiocyanate Exhibits No Anticancer Activity in MDA-MB-231 Breast Cancer Cells.

Authors:  Md Abu Sayeed; Massimo Bracci; Veronica Ciarapica; Marco Malavolta; Mauro Provinciali; Ernesta Pieragostini; Simona Gaetani; Federica Monaco; Guendalina Lucarini; Venerando Rapisarda; Roberto Di Primio; Lory Santarelli
Journal:  Int J Mol Sci       Date:  2018-01-04       Impact factor: 5.923

Review 3.  Apigenin in cancer therapy: anti-cancer effects and mechanisms of action.

Authors:  Xiaohui Yan; Miao Qi; Pengfei Li; Yihong Zhan; Huanjie Shao
Journal:  Cell Biosci       Date:  2017-10-05       Impact factor: 7.133

4.  Beclin1 overexpression suppresses tumor cell proliferation and survival via an autophagy‑dependent pathway in human synovial sarcoma cells.

Authors:  Jialin Zhu; Yongsong Cai; Ke Xu; Xiaoyu Ren; Jian Sun; Shemin Lu; Jinghong Chen; Peng Xu
Journal:  Oncol Rep       Date:  2018-07-25       Impact factor: 3.906

5.  TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1.

Authors:  Tianyu Han; Meng Guo; Mingxi Gan; Bentong Yu; Xiaoli Tian; Jian-Bin Wang
Journal:  Autophagy       Date:  2018-09-20       Impact factor: 16.016

Review 6.  Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.

Authors:  Claudia Riccardi; Domenica Musumeci; Marco Trifuoggi; Carlo Irace; Luigi Paduano; Daniela Montesarchio
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-26

Review 7.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.

Authors:  Minru Liao; Rui Qin; Wei Huang; Hong-Ping Zhu; Fu Peng; Bo Han; Bo Liu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

Review 8.  Autophagy as a therapeutic target in pancreatic cancer.

Authors:  Max Piffoux; Erwan Eriau; Philippe A Cassier
Journal:  Br J Cancer       Date:  2020-09-15       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.